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Abstract
Purpose Complex abdominal wall hernia repair (CAWHR) is a challenging procedure. Mesh prosthesis is indicated, but the use
of synthetic mesh in a contaminated area may add to overall morbidity. Biological meshes may provide a solution, but little is
known about long-term results. The aim of our study was to evaluate clinical efficacy and patient satisfaction following
Strattice™ (PADM) placement.
Methods In this cohort study, all patients operated for CAWHRwith PADM in three large community hospitals in Germanywere
included. Patients underwent abdominal examination, an ultrasound was performed, and patients completed quality-of-life
questionnaires. The study was registered in ClinicalTrials.gov under Identifier NCT02168231.
Results Twenty-seven patients were assessed (14 male, age 67.5 years, follow-up 42.4 months). The most frequent postoperative
complication was wound infection (39.1%). In no case, the PADM had to be removed. Four patients had passed away. During
outpatient clinic visit, six out of 23 patients (26.1%) had a recurrence of hernia, one patient had undergone reoperation. Five
patients (21.7%) had bulging of the abdominal wall. Quality-of-life questionnaires revealed that patients judged their scar with a
median 3.5 out of 10 points (0 = best) and judged their restrictions during daily activities with a median of 0 out of 10.0 (0 = no
restriction).
Conclusions Despite a high rate of wound infection, no biological mesh had to be removed. In some cases, therefore, the
biological meshes provided a safe way out of desperate clinical situations. Both the recurrence rate and the amount of bulging
are high (failure rate 47.8%). The reported quality of life is good after repair of these complex hernias.
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Introduction
Incisional hernia is a common complication after abdominal
surgery. Incidences range from 3 to 20% in the general popu-
lation [1–7] with an increased incidence of 26 up to 39% in
patients suffering of obesity or aortic aneurysms [2, 7–19].
Currently, incisional hernias are most often reinforced with
mesh material [20, 21]. The use of mesh radically lowered
the 10-year recurrence rates after incisional hernia repair
[20]. There are various mesh prosthesis available (convention-
al synthetic meshes, biological meshes, and since recently also
biosynthetic meshes (i.e., slowly resorbable synthetic
meshes)) [22–24]. Conventional synthetic meshes are still
used most often in general practice, and polypropylene mesh
is the most popular product [25].
There are various reasons, like mesh infections,
enterocutaneous fistulas, burst abdomen, and anastomotic
leakage, that could turn an ‘uncomplicated’ ventral hernia
repair into a complex abdominal wall hernia repair
(CAWHR) [26].
The grade of contamination is an important factor in the
treatment of incisional hernia. To classify the amount of con-
tamination, the Ventral Hernia Working Group (VHWG) de-
veloped a hernia grading system to classify the different
grades of contamination and its treatment complexity in ab-
dominal wall hernia repair (grade 1: low risk to grade 4: in-
fected) [27]. In potentially contaminated and infected
incisional hernia the use of conventional synthetic mesh is
controversial and might lead to a higher morbidity and even
mortality. In case of an infected synthetic mesh, the mesh
should be removed completely to achieve complete wound
healing [28]. Patients often have multiple comorbidities and
risk factors that increase the risk for postoperative complica-
tions and hernia recurrence. In order to provide the safest
individual treatment strategies to high morbidity patients, a
classification for complex abdominal wall hernias was defined
to facilitate the choice for CAWHR concepts [29].
Patients who need CAWHR often undergo strictly planned,
staged repair of their hernia defect [30]. Part of a different
treatment strategy for CAWHR is the use of biological mesh
instead of synthetic mesh in a one-stage procedure. Biological
mesh is however only seldom used, since costs per prosthesis
are high and little is known about long-term results. In this
study, the use of Strattice™mesh was evaluated. Strattice™ is
a decellularized, intact, non-cross-linked porcine acellular der-
mal matrix, derived from porcine dermis [31]. The study is
initiated after a nationwide German questionnaire of the ROKI
Group [32]. The aim of this study was to evaluate clinical
efficacy and patient satisfaction following Strattice™ place-
ment in patients treated for CAWHR in three academic and
peripheral hospitals in Germany. In this study, Strattice™ is




A cohort study was performed in three large community hos-
pitals in Germany (both academic and peripheral centers).
Patients were identified retrospectively and were invited to
an outpatient clinic appointment. Ethical approval for this
study was obtained from the Ethics Board of the Johann
Wolfgang Goethe University Frankfurt, Germany. After ethi-
cal approval from the Johann Wolfgang Goethe University
Frankfurt, ethical approval was obtained from all local ethical
committees in the participating hospitals.
Patients
Patients were eligible for inclusion in the cohort if they had
been operated with PADM for the indication CAWHR in one
of the participating centers in Germany. CAWHRwas defined
as the repair for a potentially contaminated to infected hernia,
which is grade 3 to grade 4 according to the system developed
by the VHWG [27]. Patients had to provide written informed
consent to participate in the study.
Procedure
Patients were identified by the surgeons of the participating
centers. The surgeons contacted all their patients and gave
them—if they were interested—additional information about
participation in the study. After written informed consent was
obtained, patients were invited to an appointment in the out-
patient clinic.
Patients were interviewed to collect baseline parameters,
and to assess their medical history. Baseline parameters were
defined as age, gender, BMI, severity of co-morbidity score
[33], length of follow-up, smoking history, and occupational
heavy lifting. The assessment of their medical history focused
on medical conditions like COPD/chronic coughing, steroid
use, malignancy, diabetes, general abdominal operations, and
specific abdominal wall operations.
All patients underwent abdominal wall examination to as-
sess the presence of a hernia recurrence or bulging of the
abdominal wall. An abdominal wall ultrasound was per-
formed in case of doubt. Patients completed quality-of-life
questionnaires to assess patient satisfaction. The EuraHS
quality-of-life questionnaires were used to assess patients’
quality of life [33, 34]. The STROBE statement was followed
[35].
The acquired data was registered in the standardized case
record forms of the incisional ventral hernia route in the
EuraHS Database (http://www.eurahs.eu/). These case record
forms were registered in a private group and were only
accessible to the members of this study group.
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Outcomes
The primary outcome for this study was recurrence of hernia
and / or the bulging of the abdominal wall after PADM repair.
Both incisional hernia and the recurrence of incisional hernia
were defined as any abdominal wall gap with or without bulge
in the area of a postoperative scar perceptible or palpable by
clinical examination or medical imaging [36]. Bulging of the
abdominal wall was defined as a substantial increase in ab-
dominal circumference, not explicable by weight gain, in the
absence of a palpable or objectifiable fascia defect, and ob-
served by either the patient or the doctor [37–39]. All patients
were diagnosed by clinical examination. In case of doubt,
abdominal wall medical imaging (i.e., ultrasound and/or CT
scan) was performed to confirm or reject the diagnosis.
Secondary outcomes in this study included postoperative
complications, i.e., wound infection, mesh infection, intra-
abdominal and/or skin abscess, seroma, hematoma, necrotic
abdominal wall, fistulas, and burst abdomen. The occurrence
of mesh explantation was also recorded, just like additional
abdominal operations, and quality-of-life parameters.
Complications were classified according to Dindo and
Clavien [40].
Statistical analysis
Continuous variables were summarized by using means and
ranges; categorical values were summarized with frequencies
and percentages. Quality-of-life questionnaires were summa-
rized with medians and ranges. The database was made in
Microsoft Excel version 2016 (MSO 16.0.11029.20045) and
analyzed in SPSS version 26.0 (version 26.0.0.0). The data
was assessed for normality by performing a Shapiro-Wilk’s
test (p > 0.05), and a visual inspection of their histograms,
normal Q-Q plots, and box plots showed that most of the data
was approximately normally distributed. Thereafter, the skew-
ness and kurtosis of the data were calculated. If the Z-values
were in the desired range of − 1.96 to 1.96, the data was
presented as median (range). If the data was not normally
distributed, it was presented as median (interquartile ranges).
There was no data safety committee overseeing the study. The
study was registered in ClinicalTrials.gov under Identifier
NCT02168231.
Role of the funding source
Funding to execute this study was obtained from LifeCell
Corporation, a KCI company, Branchburg, NJ, USA. The
funder of the study had no role in study design, data collection,
data analysis, data interpretation, or writing of the report. The
corresponding author had full access to all the data in the study




A total of 27 patients met the inclusion criteria, of whom four
were deceased. These four patients had passed away after
surgery after 5, 22, 50, and 904 days, respectively. Twenty-
three patients have been assessed for long-term follow-up (14
male, mean age 67.5 years, mean follow-up 42.4 months).
Their median BMI was 27.4 (interquartile range 24.1–32.2).
The median SOC score was 2 for all registered comorbidities
(Table 1).
Perioperative information
The risk factor seen most often was a personal history of
previous abdominal wall hernia operation (Table 2). The esti-
mated diameter of the hernia was median 18.25 cm (range 10–
30 cm). The median defect size of the hernia was 357 cm2
(range 100–900 cm2). The operation was elective in 16 pa-
tients, and an emergency procedure in five patients. In two
patients, it was unknown whether it was an elective or an
emergency procedure. All perioperative information was re-
corded retrospectively and whenever possible verified with
patients during their outpatient visit.
The hernia was located most often in the midline in the
areas M2, M3, M4, and M5. Only three patients had under-
gone a previous hernia repair. These patients had undergone a
median number of two previous hernia repairs (range one to
three operations). All patients were operated under general
anesthesia. Most patients received a single dose of antibiotics
preoperatively (n = 11). In none of the patients, preoperative
botulinum toxin or progressive preoperative pneumoperitone-
um was used.
The wound classification was median CDCwound class III
(contaminated) [41, 42]. In ten patients, a part of the bowel
had to be removed during operation. The abdomen was closed
with a combined component separation and mesh placement
in 15 patients. In eight patients, mesh repair sufficed. All pa-
tients received a Strattice™ mesh. The most frequently used
mesh size was 400 cm2. The mesh was fixated with
transfascial sutures, and the entire hernia defect could be
closed in all patients. There were no intraoperative surgical
complications. The median length of stay after operation
was 15 days (range 7–124 days).
Postoperative outcomes
The most frequent postoperative complication was wound in-
fection (39.1%). In six patients, it was a superficial wound
infection. In no case, the PADM had to be removed. Other
intrahospital complications were a bleeding complication in
one patient, and in three patients there were general
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complications (acute renal failure, pleural effusion, peritoni-
tis). In five patients, there were no intrahospital complications.
The classification of the complications according to Dindo
and Clavien was median grade IIIb (intervention under gener-
al anesthesia) [40].
Long-term outcomes
By the time of outpatient clinic visit, six out of 23 patients
(26.1%) had a recurrence of hernia, of whom one patient
had undergone reoperation. All recurrences were found at
the original hernia site. Another five patients (21.7%) had
an asymptomatic bulging of the abdominal wall. Fourteen
patients (60.1%) were evaluated by clinical examination
combined with medical imaging, seven patients (30.4%)
were evaluated with clinical examination, and in two pa-
tients (8.7%), it was unknown whether clinical examina-
tion was used with or without medical imaging. Patients
with a recurrence or bulging often wore an abdominal
binder.
Quality-of-life parameters
Patients reported a good quality of life on the EuraHS quality-
of-life questionnaires (Table 3). The quality-of-life data are
presented as median scores. Patients had no pain in rest or
during activities, and the worst pain they had felt in the last
week was no pain, although one patient (4.3%) reported a pain
score of 10. Most patients had no restriction in their daily
activities. They experienced only minor limitations in their
activities outside the house. Three patients, however, reported
severe restrictions in their daily activities (13.1%). Patients
that were capable of doing sports or heavy labor experienced
limited restrictions. However, in the latter two situations, there
were six and seven patients, respectively, that could not per-
form these activities.
Discussion
These results show that despite a high rate of postoperative
wound infection no biological mesh had to be removed. Both
the recurrence rate and the amount of bulging after long-term
follow-up are significant (failure rate of 47.8%). The reported
quality of life is good after repair of these complex hernias.
The use of biological mesh in complex abdominal wall
hernia is relatively new. There are not that many studies com-
parable with ours regarding methodology and characteristics.
The RICH study, in which the results of Strattice™ mesh
(Acelity™, non-cross-linked, acellular porcine dermis) were
analyzed, seems to have the most similarities in methodolog-
ical approach [31]. Itani et al. found a recurrence rate of 28%
after 2 years [31]. This is comparable with the outcome of this
study (26.1%). In the study of Maxwell et al. [43], a much
Table 1 Baseline criteria
Mean follow-up (mean) 42.4 months
Gender: male vs. female 14 vs. 9
Age (mean) (range) 67.5 years (48–90)
BMI (median) (interquartile range) 27.4 (24.1–32.2)
SOC score (median) (range) 2 (1–3)
Comorbidities (number of patients (percentage))
Arterial hypertension 9 (39.1%)
Cardiac disease 6 (26.1%)
Diabetes mellitus type II 8 (34.8%)
Malignant disease 2 (8.7%)
Pulmonary disease (COPD/asthma) 3 (13%)
Renal disease 5 (21.7%)
Other: peritonitis, fistula, cachexia, hypothyroidism, portal vein thrombosis 8 (34.8%)
No comorbidities 5 (21.7%)
Smoking (daily/occasional smoking) 6 (26.1%)
Ex-smoker 7 (30.4%)
Table 2 Risk factors for complex abdominal wall hernia (number of
patients (percentage))
Abdominal aortic aneurysm 1 (4.3%)
Anticoagulation therapy 2 (8.7%)
Chronic use of cortisone 1 (4.3%)
No other risk factors 7 (30.4%)
Personal history of previous abdominal wall hernia operation 9 (39.1%)
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lower recurrence rate of 11.2% was found after median
20.9 months. Patients received an additional CT scan to con-
firm recurrence. Patients with bulging were excluded from the
study. This could lead to certain bias, since bulging is also an
unfavorable outcome. In a study by Rosen et al., a much
higher recurrence rate of over 50% was found after 3 years
of follow-up. In Rosen’s study, the following meshes were
assessed: Strattice™ (same mesh; non-cross-linked porcine
dermal matrix), Alloderm™ (non-cross-linked human dermal
matrix), Biodesign® (porcine small intestinal submucosa
sheet), XenMatrix™ (non-cross-linked porcine dermal ma-
trix), and BioA® (biosynthetic web scaffold made of 67%
polyglycolic acid (PGA): 33% trimethylene carbonate) [44].
This high recurrence rate could possibly be explained by a
longer follow-up. Another difference is the use of a number
of different meshes, which could also lead to a higher recur-
rence rate. Also Itani et al. did not assess the amount of bulg-
ing in their study [31]. In this study, a bulging rate of 21.7%
was found. This bulging rate is lower compared with data of a
previous study from our study group (bulging rate 50.6%
[45]). This difference could be explained by the difference in
material, cross-linked versus non-cross-linked porcine acellu-
lar dermal matrix.
The patients that were enrolled in this study were operated
in three hospitals in Germany. Each hospital had at least one
surgeon dedicated to abdominal wall surgery. These surgeons
treated their patients with PADM. The surgeons also united
themselves in the ROKI group to assess their results of PADM
repair [32]. Aside from the multicenter character of the study,
another important asset was the assessment of quality-of-life
parameters. This is only rarely studied in complex abdominal
wall hernia repair. These patients suffer not only from a com-
plex abdominal wall hernia but also of multiple comorbidities
and risk factors that increase the risk of postoperative compli-
cations. A previous study of Roth et al. published about
quality-of-life parameters in this specific patient group [46].
In this study, they used the short form-12 health survey [47]
and found an improvement of the quality-of-life indicators
after 12 months compared with the baseline. This improve-
ment, however, was not significant. In the current study, no
comparison was made with the preoperative situation, since
these data were not prospectively obtained.
The most frequent postoperative complication in this study
was wound infection (39.1%). This percentage is slightly low-
er than in a recent study of Roth et al. [46]. Roth et al. found
43%wound infections after acellular dermal matrix placement
(FlexHD® and Strattice™). Themedian follow-up was 1 year.
The wound infection percentage in our study, however, was
somewhat higher than previous studies by Itani el al. [31]
(35%), Diaz et al. [48] (33%), Maxwell et al. [43] (26.2%),
Helton et al. [49] (23%), and Cheng et al. [50] (5%). All
studies [31, 43, 48–50] contained a high percentage of patients
that had a hernia classified as clean or clean contaminated
[27]. In contrast to our cohort with only contaminated hernias,
this could have led to a lower postoperative infection rate. In
this study, PADM did not have to be removed representing a
better result than found in the studies of Diaz et al. [48] (five
mesh removals; 6.7%) and Helton et al. [49] (five mesh re-
movals; 9.8%).
There is contrasting evidence available regarding biologi-
cal meshes and their characteristics. A recent review by
Sainfort et al. [51] assessed the literature about biologic ab-
dominal wall matrices. They concluded that there were no
high-level evidence data on biologic prostheses that allowed
prioritization of the various biologic prostheses according to
their characteristics or their different manufacturing processes.
Table 3 Outcomes measured
with the EuraHS quality-of-life
scale [33, 34] after complex ab-
dominal wall hernia repair with
PADM. Scores are expressed as
median scores (range)
Pain at the side of the hernia
0 = no pain, 10 = worst pain imaginable
Pain in rest (lying down) 0—no pain (range 0–6)
Pain during activities (walking, biking, sports) 0—no pain (range 0–8)
Pain felt during the last week 0—no pain (range 0–10)
Restrictions of activities because of pain or discomfort at the site of the hernia
0 = no restriction, 10 = completely restricted, X = The patient does not perform this activity
Restriction from daily activities (inside the house) 0 – no restrictions (range 0–10)
Restriction outside the house (walking, biking, driving) 1.5 (range 0–10; 2 times X)
Restriction during sports 1 (range 0–7; 6 times X)
Restriction during heavy labor 2 (range 0–9; 7 times X)
Cosmetic discomfort
0 = very beautiful, 10 = extremely ugly
Shape of your abdomen 4 (range 0–10)
Site of the hernia 3.5 (range 0–10)
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A more recent study by Tripolli et al. [52] assessed the litera-
ture on Permacol™, Strattice™, Surgisis®, Tutomesh™, and
XenMatrix™. Eleven studies of a poor methodological qual-
ity were assessed and included in the review. They concluded
that there was a striking statistical variability in the outcomes
of all meshes. The only significant finding in their study was
that cross-linked meshes had a significantly lower recurrence
rate at 12 months than non-cross-linked meshes.
Incisional hernia repair is associated with overall finan-
cial losses [53]. Especially biological meshes are expen-
sive and rarely used [54]. In the current study, no cost
analysis was performed. In a study of Huntington et al.,
a cost analysis was performed comparing AlloDerm®,
AlloMax™, FlexHD®, Strattice™, and XenMatrix™
[55]. In that study, Strattice™ was the second most ex-
pensive mesh (mesh charge per patient US$ 31,875 ±
17,960 and total costs hospital stay per patient US$
140,394 ± 80,709). The mesh charges and total costs of
hospital stay per patient seem higher in the USA than they
are in the The Netherlands and Germany; however, these
data are illustrative for the current ratios. In another study
by Byrge et al., a head-to-head comparison was performed
between Permacol™ and Strattice™ meshes in a similar
patient group. The costs of the mesh were significantly
higher for Strattice™ (median cost $8940) compared with
Permacol™ (median costs $1600). The use of Permacol™
resulted in a savings of $181,320 with similar clinical
outcomes when compared with Strattice™ [56].
Limitations
The mesh in this study (PADM) is not used on a large
scale, and therefore there is only a limited number of
patients that can be assessed. As only patients with poten-
tially contaminated and contaminated abdominal wall her-
nia were evaluated, there was only a relatively small pa-
tient number to include in this study. Although there were
more hospitals that work with PADM, not all surgeons
seemed that keen to share their data. Another limitation
is the design of the study (a cross-sectional cohort study).
Data were partly retrospective and partly prospectively
collected. This could have led to a bias.
Conclusion
The data of this study show that despite a high rate of postop-
erative wound infection, no biological mesh had to be re-
moved. There was a high failure rate of 47.8% due to recur-
rences and bulging. However, patients reported a good quality
of life after repair of these complex hernias without relevant
limitation in everyday life activities.
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